Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CLL according to the NCI Working Group criteria.~* Male and female patients of age \>18 and ≤75 years~* Patients relapsed/refractory within 1 month after conventional chemotherapy (\>1 polychemotherapy regimen) or relapsed within 3 months after autologous bone marrow transplantation~* ECOG performance score of ≤2~* Lymphocytes ≥10.0x10\^9/L and platelets \>75.0x10\^9/L after recovery from a previous therapy~* Percentage of CD19+/CD5+ leukemic cells \>50%~* Adequate cardiac, pulmonary and renal function, as defined by LVEF \>45%, FEV \>50% and creatinine ≤1.5 ULN or creatinine clearance ≥50ml/min~* Serum bilirubin \<1.5xULN, AST and ALT \<2.5xULN~* Serum potassium, phosphorus, total calcium, magnesium \>LLN~* Normal values for FT4 and TSH (patients may be on thyroid hormone replacement)~* Negative test for beta-HCG for women in fertile age~* Documentation of written informed consent to participate in the trial~* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.~Exclusion Criteria:~* Patients with Autoimmune haemolytic anaemia, Autoimmune Thrombocytopenic Purpura and Fischer Evans Syndrome.~* Patients with other autoimmune diseases.~* Patients with a marked baseline prolongation of QTc interval (e.g. repeated demonstration of a QTc interval \>450 ms).~* Patients with history of additional risk factors for torsade de pointes (e.g. hearth failure, family history of Long QT Syndrome)~* The use of concomitant medications with potential risk of torsade de pointes and/or that can prolong QTc interval~* Prior treatment with an HDAC inhibitor.~* Treatment with Rituximab or Alemtuzumab within 90 days prior to study therapy.~* Patients HIV positive, patients with active EBV, HBV, HCV infection or liver cirrhosis~* Patients with active uncontrolled viral or bacterial or mycotic infection.~* Major surgeries within 4 weeks from study start or not fully recovered from any previous surgical procedure.~* Presence of any medical or psychiatric condition which may limit full compliance with the study or increase the risk associated with study participation or study drug administration.~* Patients in treatment with corticosteroids within 1 month before study start~* Significant cardiovascular disease (i.e., uncontrolled arrhythmias, unstable angina), or a major thromboembolic event (myocardial infarction, stroke, transient ischemic attack, pulmonary embolism, or non-catheter-related deep-vein thrombosis) in the last 6 months.~* Uncontrolled hypertension.~* Malabsorption syndromes.~* Breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ITF2357 (Type: EXPERIMENTAL): ITF2357 was supplied as hard gelatine capsules for oral administration at the strength of 100 or 50 mg. Patients had to receive ITF2357 100 mg x 2/die at 12-hour intervals, in fed conditions, for three consecutive months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility